American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach
Open accessThe DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
Objective The aim of this Disease State Clinical Review is to provide a practical approach to patients with newly diagnosed adrenocortical carcinoma, as well as to follow-up and management of patients with persistent or recurrent disease.Methods This is a case-based clinical review. The provided recommendations are based on evidence available from randomized prospective clinical studies, cohort studies, cross-sectional and case-based studies, and expert opinions.Results Adrenocortical carcinoma is a rare malignancy, often with poor outcomes. For any patient with an adrenal mass suspicious for adrenocortical carcinoma, the approach should include prompt evaluation with detailed history and physical exam, imaging, and biochemical adrenal hormone assessment. In addition to adrenal-focused imaging, patients should be evaluated with chest-abdomen-pelvis cross-sectional imaging to define the initial therapy plan. Patients with potentially resectable disease limited to the adrenal gland should undergo en bloc open surgery by an expert surgeon. For patients presenting with advanced or recurrent disease, a multidisciplinary approach considering curative repeat surgery, local control with surgery, radiation therapy or radiofrequency ablation, or systemic therapy with mitotane and/or cytotoxic chemotherapy is recommended.Conclusion As most health care providers will rarely encounter a patient with adrenocortical carcinoma, we recommend that patients with suspected adrenocortical carcinoma be evaluated by an expert multidisciplinary team which includes clinicians with expertise in adrenal tumors, including endocrinologists, oncologists, surgeons, radiation oncologists, pathologists, geneticists, and radiologists. We recommend that patients in remote locations be followed by the local health care provider in collaboration with a multidisciplinary team at an expert adrenal tumor program.Abbreviations ACC = adrenocortical carcinoma; ACTH = adrenocorticotropic hormone; BRACC = borderline resectable adrenocortical carcinoma; CT = computed tomography; DHEAS = dehydroepiandrosterone sulfate; EDP = etoposide, doxorubicin, cisplatin; FDG = 18 F-fluorodeoxyglucose; FNA = fine-needle aspiration; HU = Hounsfield units; IVC = inferior vena cava; LFS = Li-Fraumeni syndrome; MEN1 = multiple endocrine neoplasia type 1; MRI = magnetic resonance imaging; OAC = oncocytic adrenocortical carcinoma; PC = palliative care; PET = positron emission tomography.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mitotane is the only agent approved by the FDA and EMA as the first-line agent in managing metastatic adrenocortical carcinoma for over six decades150.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Prognostic significance of morphologic parameters in renal cell carcinoma
Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198210000-00007 · Cited by 2,724 · cited 1×
“The diagnosis can generally be made using routine hematoxylin and eosin staining, from which the Weiss score can be derived (Table 3), providing the final diagnosis of an ACC (Weiss score >3) (23,24).”
MethodFassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566 · cited 1×
“A careful pathologic review will also provide the correct stage (Table 5) (32,33), with any extra-capsular extension with infiltration of the adipose tissue being the most important differentiator between stage 2 and stage 3, which is not always obvious prior to surgery.”
BackgroundSelf-citationFassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961 · cited 10×
“However, the initial presentation with ACC during pregnancy has been reported, and in these situations, adrenalectomy is recommended (3).”
BackgroundMethodInfluentialSelf-citationComparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920 · cited 1×
“The diagnosis can generally be made using routine hematoxylin and eosin staining, from which the Weiss score can be derived (Table 3), providing the final diagnosis of an ACC (Weiss score >3) (23,24).”
MethodElse, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Self-citationCombination Chemotherapy in Advanced Adrenocortical Carcinoma
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 873 · cited 1×
“Despite the only modest efficacy of EDP-mitotane, the response rate was higher compared to SZ-mitotane (response rate 9%, with median progression-free survival of 2 months) (79).”
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 764 · cited 1×
“These observational studies demonstrated that adjuvant mitotane therapy was associated with prolonged recurrence-free survival and possibly greater overall survival when compared to no adjuvant therapy amongst patients with locoregional/stage 3 ACC (Table 5) (53).”
BackgroundLuton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717 · cited 1×
“Up to 60% of patients with ACC have evidence of clinical hormone excess, with autonomous glucocorticoid production being the most common (10,11).”
BackgroundComprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., Lerario, A. M., Else, T., Knijnenburg, T. A., Ciriello, G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.002 · Cited by 657
Self-citationIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
AME Position Statement on adrenal incidentaloma
Terzolo, M., Stigliano, A., Chiodini, I., Loli, P., Furlani, L., Arnaldi, G., Reimondo, G., Pia, A., Toscano, V, Zini, M., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1147 · Cited by 520 · cited 1×
“Available imaging techniques include CT, MRI, and 18FDG-PET (5,6,104).”
MethodZeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
Self-citationAdrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493
Fleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479 · cited 1×
“This often necessitates the use of spironolactone and/or potassium replacement (103).”
BackgroundSelf-citationUrine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors
Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1565 · Cited by 458 · cited 2×
“Urine steroid profiling can further reveal increased steroid precursors and metabolites even in clinically nonfunctioning ACC (15,16).”
BackgroundAbiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435 · cited 1×
“Hyperaldosteronism is rarely associated with ACC, described in around 2 to 7% of patients (12,13).”
BackgroundAdrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1167 · Cited by 372 · cited 1×
“The Chompret testing criteria for TP53 (LFS) suggest testing everyone with a diagnosis of ACC, which is justified because a significant proportion of patients carry de novo mutations, and a family history can be negative (44,45).”
MethodClinical management of adrenocortical carcinoma
Fassnacht, M., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.008 · Cited by 349 · cited 1×
“Up to 60% of patients with ACC have evidence of clinical hormone excess, with autonomous glucocorticoid production being the most common (10,11).”
BackgroundMajor Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection
Beuschlein, F., Weigel, J., Saeger, W., Kroiss, M., Wild, V., Daffara, F., Libé, R., Ardito, A., Al Ghuzlan, A., Quinkler, M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3182 · Cited by 342 · cited 1×
“A Ki67 index of >10% is regarded as an unfavorable prognostic marker (28,29).”
BackgroundSensitivity and predictive value of criteria for p53 germline mutation screening
CHOMPRET, A., ABEL, A., STOPPA-LYONNET, D., BRUGIÈRES, L., PAGÈS, S., FEUNTEUN, J., & BONAÏTI-PELLIÉ, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.1.43 · Cited by 341 · cited 1×
“The Chompret testing criteria for TP53 (LFS) suggest testing everyone with a diagnosis of ACC, which is justified because a significant proportion of patients carry de novo mutations, and a family history can be negative (44,45).”
MethodFassnacht, M., Berruti, A., Baudin, E., Demeure, M. J., Gilbert, J., Haak, H., Kroiss, M., Quinn, D. I., Hesseltine, E., Ronchi, C. L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70081-1 · Cited by 339 · cited 1×
“Despite the overall lack of efficacy, there was a small subset of patients with true responses to therapy (83).”
BackgroundAdrenocortical Oncocytic Tumors: Report of 10 Cases and Review of the Literature
Bisceglia, M., Ludovico, O., Di Mattia, A., Ben-Dor, D., Sandbank, J., Pasquinelli, G., Lau, S. K., & Weiss, L. M. (2004) · International Journal of Surgical Pathology · doi:10.1177/106689690401200304 · Cited by 318
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center
Ayala-Ramirez, M., Jasim, S., Feng, L., Ejaz, S., Deniz, F., Busaidy, N., Waguespack, S. G., Naing, A., Sircar, K., Wood, C. G., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0519 · Cited by 293 · cited 1×
“The majority of patients with ACC present with locally advanced disease (34% with stage 3) or metastatic disease (26% with stage 4) (74).”
BackgroundSelf-citationBrix, D., Allolio, B., Fenske, W., Agha, A., Dralle, H., Jurowich, C., Langer, P., Mussack, T., Nies, C., Riedmiller, H., et al. (2010) · European Urology · doi:10.1016/j.eururo.2010.06.024 · Cited by 286 · cited 1×
“In addition to patients with ACC presenting with stage 4 disease, almost 60 to 70% of patients with localized ACC develop local and more commonly distant recurrence after having surgery with curative intent (62,77,78).”
BackgroundRadiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases
Wood, B. J., Abraham, J., Hvizda, J. L., Alexander, H. R., & Fojo, T. (2003) · Cancer · doi:10.1002/cncr.11084 · Cited by 264 · cited 2×
“For patients with unresectable recurrences or metastatic lesions or for those who opt against surgery, local therapies such as radiofrequency ablation, percutaneous laser ablation, cryoablation, microwave ablation, and transcatheter arterial chemoembolization approaches may provide local control (68,69).”
BackgroundMethodLibé, R., Borget, I., Ronchi, C. L., Zaggia, B., Kroiss, M., Kerkhofs, T., Bertherat, J., Volante, M., Quinkler, M., Chabre, O., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv329 · Cited by 263 · cited 1×
“A Ki67 index of >10% is regarded as an unfavorable prognostic marker (28,29).”
BackgroundBancos, I., Taylor, A. E., Chortis, V., Sitch, A. J., Jenkinson, C., Davidge-Pitts, C. J., Lang, K., Tsagarakis, S., Macech, M., Riester, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30218-7 · Cited by 250 · cited 3×
“Urine steroid profiling can further reveal increased steroid precursors and metabolites even in clinically nonfunctioning ACC (15,16).”
BackgroundMethodSelf-citationHigh Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors
Sbiera, S., Schmull, S., Assie, G., Voelker, H.-U., Kraus, L., Beyer, M., Ragazzon, B., Beuschlein, F., Willenberg, H. S., Hahner, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0653 · Cited by 242 · cited 1×
“However, SF1 has emerged as the most reliable marker to confirm adrenocortical origin (27).”
BackgroundLaparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma
Miller, B. S., Ammori, J. B., Gauger, P. G., Broome, J. T., Hammer, G. D., & Doherty, G. M. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0532-2 · Cited by 221 · cited 1×
“In addition to patients with ACC presenting with stage 4 disease, almost 60 to 70% of patients with localized ACC develop local and more commonly distant recurrence after having surgery with curative intent (62,77,78).”
BackgroundDinnes, J., Bancos, I., Ferrante di Ruffano, L., Chortis, V., Davenport, C., Bayliss, S., Sahdev, A., Guest, P., Fassnacht, M., Deeks, J. J., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0461 · Cited by 219
Self-citationElse, T., Williams, A. R., Sabolch, A., Jolly, S., Miller, B. S., & Hammer, G. D. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2856 · Cited by 201
Self-citationPD-1 Blockade in Advanced Adrenocortical Carcinoma
Raj, N., Zheng, Y., Kelly, V., Katz, S. S., Chou, J., Do, R. K. G., Capanu, M., Zamarin, D., Saltz, L. B., Ariyan, C. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01586 · Cited by 200
Sbiera, S., Leich, E., Liebisch, G., Sbiera, I., Schirbel, A., Wiemer, L., Matysik, S., Eckhardt, C., Gardill, F., Gehl, A., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1367 · Cited by 191
Radiotherapy in adrenocortical carcinoma
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer · doi:10.1002/cncr.24331 · Cited by 189 · cited 2×
“The study demonstrated that radiotherapy may play an important role in the care of patients with advanced metastatic ACC (92).”
BackgroundAdrenal Neoplasms: CT-guided Radiofrequency Ablation—Preliminary Results
Mayo-Smith, W. W., & Dupuy, D. E. (2004) · Radiology · doi:10.1148/radiol.2311031007 · Cited by 183 · cited 1×
“For patients with unresectable recurrences or metastatic lesions or for those who opt against surgery, local therapies such as radiofrequency ablation, percutaneous laser ablation, cryoablation, microwave ablation, and transcatheter arterial chemoembolization approaches may provide local control (68,69).”
BackgroundSunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial
Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1419 · Cited by 175 · cited 1×
“It is important to note that in most patients with ACC who are treated with mitotane, efficacy of subsequent therapies might be hampered by increased drug metabolism by induction of the hepatic CYP3A4 system (82).”
BackgroundLe Tourneau, C., Hoimes, C., Zarwan, C., Wong, D. J., Bauer, S., Claus, R., Wermke, M., Hariharan, S., von Heydebreck, A., Kasturi, V., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0424-9 · Cited by 173
The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population Based Study
Sharma, E., Dahal, S., Sharma, P., Bhandari, A., Gupta, V., Amgai, B., & Dahal, S. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3503w · Cited by 160 · cited 2×
“These estimates have recently been confirmed by additional analyses of National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) data from 18 registries (1).”
BackgroundResultPhase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Habra, M. A., Stephen, B., Campbell, M., Hess, K., Tapia, C., Xu, M., Rodon Ahnert, J., Jimenez, C., Lee, J. E., Perrier, N. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0722-x · Cited by 160
Self-citationGrubbs, E. G., Callender, G. G., Xing, Y., Perrier, N. D., Evans, D. B., Phan, A. T., & Lee, J. E. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0716-x · Cited by 158
Fassnacht, M., Johanssen, S., Fenske, W., Weismann, D., Agha, A., Beuschlein, F., Führer, D., Jurowich, C., Quinkler, M., Petersenn, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0803 · Cited by 157
SCHULTE, H. M., BENKER, G., REINWEIN, D., SIPPELL, W. G., & ALLOLIO, B. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-5-1426 · Cited by 156 · cited 1×
“For immediate control of hypercortisolism, etomidate, likewise a very potent 11β-hydroxylase inhibitor, can be used (roughly ~1/10 of anesthetic dose) (102).”
BackgroundChortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2851 · Cited by 154
The role of surgery in the management of recurrent adrenocortical carcinoma
Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2559 · Cited by 154 · cited 1×
“Any therapy at this stage will be palliative; however, aggressive resection of distant disease may provide higher long-term survival rates compared to those who do not undergo surgery (61,64).”
BackgroundTelemedicine and Palliative Care: an Increasing Role in Supportive Oncology
Worster, B. K., & Swartz, K. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0600-y · Cited by 153 · cited 1×
“New technologies such as telemedicine provide an opportunity for the care of patients with advanced metastatic ACC who prefer to have their care at home (101).”
BackgroundNaing, A., LoRusso, P. M., Fu, S., Hong, D. S., Chen, H. X., Doyle, L. A., Phan, A. T., Habra, M. A., & Kurzrock, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.46 · Cited by 148 · cited 1×
“The combined targeting of insulin-like growth factor receptor 1 via monoclonal antibody (cixutumumab) in combination with an mTOR inhibitor (temsirolimus) resulted in stable disease in almost 40% of participants at >6 months (duration range, 6 to 21 months) (84).”
BackgroundSelf-citationWong, D., Spagnolo, D. V., Bisceglia, M., Havlat, M. F., McCallum, D., & Platten, M. A. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.08.010 · Cited by 147
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma
Megerle, F., Herrmann, W., Schlötelburg, W., Ronchi, C. L., Pulzer, A., Quinkler, M. O., Beuschlein, F., Hahner, S., Kroiß, M., Faßnacht, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02591 · Cited by 147 · cited 1×
“Adjuvant mitotane therapy is generally continued for approximately a minimum of 2 years unless limited by intolerable adverse events and/or substantial recurrences in disease despite optimal mitotane dosing (54,55).”
BackgroundBerruti, A., Grisanti, S., Pulzer, A., Claps, M., Daffara, F., Loli, P., Mannelli, M., Boscaro, M., Arvat, E., Tiberio, G. A. M., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2894 · Cited by 146
Bancos, I., Tamhane, S., Shah, M., Delivanis, D. A., Alahdab, F., Arlt, W., Fassnacht, M., & Murad, M. H. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0297 · Cited by 144
Self-citationPercutaneous CT-Guided Biopsy of Adrenal Masses: Immediate and Delayed Complications
Mody, M. K., Kazerooni, E. A., & Korobkin, M. (1995) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199505000-00017 · Cited by 139
Berruti, A., Sperone, P., Ferrero, A., Germano, A., Ardito, A., Priola, A. M., De Francia, S., Volante, M., Daffara, F., Generali, D., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0918 · Cited by 138 · cited 1×
“Sorafenib in combination with paclitaxel did not yield any responses (81), and single-agent salvage therapy with sunitinib in 35 patients with ACC was associated with a median progression-free survival of 2.”
BackgroundAdrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?
Leboulleux, S., Deandreis, D., Al Ghuzlan, A., Aupérin, A., Goéré, D., Dromain, C., Elias, D., Caillou, B., Travagli, J. P., De Baere, T., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1096 · Cited by 133 · cited 2×
“Laparoscopic resection is associated with a higher risk to develop recurrence and should be avoided when a mass is suspicious for ACC (19,20).”
BackgroundNivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
Carneiro, B. A., Konda, B., Costa, R. B., Costa, R. L. B., Sagar, V., Gursel, D. B., Kirschner, L. S., Chae, Y. K., Abdulkadir, S. A., RADEMAKER, A. W., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00600 · Cited by 132
CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma
Canu, L., Van Hemert, J. A. W., Kerstens, M. N., Hartman, R. P., Khanna, A., Kraljevic, I., Kastelan, D., Badiu, C., Ambroziak, U., Tabarin, A., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01532 · Cited by 131
Self-citationCooper, A. B., Habra, M. A., Grubbs, E. G., Bednarski, B. K., Ying, A. K., Perrier, N. D., Lee, J. E., & Aloia, T. A. (2013) · Surgical Endoscopy · doi:10.1007/s00464-013-3034-0 · Cited by 128 · cited 2×
“Laparoscopic resection is associated with a higher risk to develop recurrence and should be avoided when a mass is suspicious for ACC (19,20).”
BackgroundSelf-citationSangoi, A. R., Fujiwara, M., West, R. B., Montgomery, K. D., Bonventre, J. V., Higgins, J., Rouse, R. V., Gökden, N., & McKenney, J. K. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182152629 · Cited by 121 · cited 1×
“immunohistochemical stains that can help in the differential diagnosis and confirm adrenocortical tumor origin, such as inhibin-alpha, Melan-A, and calretinin (Table 4) (25,26).”
BackgroundIñiguez-Ariza, N. M., Kohlenberg, J. D., Delivanis, D. A., Hartman, R. P., Dean, D. S., Thomas, M. A., Shah, M. Z., Herndon, J., McKenzie, T. J., Arlt, W., et al. (2018) · Mayo Clinic Proceedings: Innovations, Quality & Outcomes · doi:10.1016/j.mayocpiqo.2017.11.002 · Cited by 116 · cited 2×
“Available imaging techniques include CT, MRI, and 18FDG-PET (5,6,104).”
BackgroundMethodSelf-citationHenning, J. E. K., Deutschbein, T., Altieri, B., Steinhauer, S., Kircher, S., Sbiera, S., Wild, V., Schlötelburg, W., Kroiß, M., Perotti, P., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01624 · Cited by 112 · cited 1×
“In a retrospective multicenter study of 145 patients with advanced ACC, gemcitabine use alone or in combination with capecitabine resulted in median progression-free survival of less than 3 months, with a very low partial response rate of 5% (80).”
BackgroundHines, J. M., Bancos, I., Bancos, C., Singh, R. D., Avula, A. V., Young, W. F., Grebe, S. K., & Singh, R. J. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.271106 · Cited by 111
Self-citationComparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma
Kerkhofs, T. M. A., Baudin, É., Terzolo, M., Allolio, B., Chadarévian, R., Mueller, H. H., Skogseid, B. M., Leboulleux, S., Mantero, F., Haak, H. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2281 · Cited by 103
Operative management for recurrent and metastatic adrenocortical carcinoma
Datrice, N. M., Langan, R. C., Ripley, R. T., Kemp, C. D., Steinberg, S. M., Wood, B. J., Libutti, S. K., Fojo, T., Schrump, D. S., & Avital, I. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23015 · Cited by 101 · cited 1×
“Any therapy at this stage will be palliative; however, aggressive resection of distant disease may provide higher long-term survival rates compared to those who do not undergo surgery (61,64).”
BackgroundAn International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma
Papathomas, T. G., Pucci, E., Giordano, T. J., Lu, H., Duregon, E., Volante, M., Papotti, M., Lloyd, R. V., Tischler, A. S., van Nederveen, F. H., et al. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000574 · Cited by 97 · cited 1×
“It is important to gain experience with these automated systems, as they often provide different, in our experience, often higher values than traditional estimates (30,31).”
BackgroundUrine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma
Chortis, V., Bancos, I., Nijman, T., Gilligan, L. C., Taylor, A. E., Ronchi, C. L., O’Reilly, M. W., Schreiner, J., Asia, M., Riester, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz141 · Cited by 93
Self-citationPostlewait, L. M., Ethun, C. G., Tran, T. B., Prescott, J. D., Pawlik, T. M., Wang, T. S., Glenn, J. A., Hatzaras, I. S., Shenoy, R. S., Phay, J. E., et al. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.12.013 · Cited by 92
Smith, C. B., Phillips, T., & Smith, T. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175474 · Cited by 90 · cited 1×
“Several oncology organizations have guidelines about PC, reflecting the need to integrate it into standard oncology care (100).”
BackgroundLongitudinal patterns of recurrence in patients with adrenocortical carcinoma
Glenn, J. A., Else, T., Hughes, D. T., Cohen, M. S., Jolly, S., Giordano, T. J., Worden, F. P., Gauger, P. G., Hammer, G. D., & Miller, B. S. (2018) · Surgery · doi:10.1016/j.surg.2018.04.068 · Cited by 88 · cited 2×
“In addition to patients with ACC presenting with stage 4 disease, almost 60 to 70% of patients with localized ACC develop local and more commonly distant recurrence after having surgery with curative intent (62,77,78).”
BackgroundSelf-citation[131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma
Hahner, S., Kreissl, M. C., Fassnacht, M., Haenscheid, H., Knoedler, P., Lang, K., Buck, A. K., Reiners, C., Allolio, B., & Schirbel, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2765 · Cited by 87
Management of Adrenocortical Carcinoma
Jasim, S., & Habra, M. A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0773-7 · Cited by 85 · cited 2×
“Radiation therapy may be offered in carefully selected patients with oligo-metastases who are not a good candidate or do not want to pursue surgery or systemic therapy (91).”
BackgroundSelf-citationWilliams, A. R., Hammer, G. D., & Else, T. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1033 · Cited by 83
Self-citationThe Evaluation of Incidentally Discovered Adrenal Masses
Vaidya, A., Hamrahian, A., Bancos, I., Fleseriu, M., & Ghayee, H. K. (2019) · Endocrine Practice · doi:10.4158/dscr-2018-0565 · Cited by 78 · cited 1×
“Available imaging techniques include CT, MRI, and 18FDG-PET (5,6,104).”
MethodSelf-citationAdrenocortical carcinoma: The management of metastatic disease
Fay, A. P., Elfiky, A. A., Teló, G. H., McKay, R. R., Kaymakcalan, M. D., Nguyen, P. L., Vaidya, A., Ruan, D. T., Bellmunt, J., & Choueiri, T. K. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.05.009 · Cited by 76 · cited 1×
“The decision to offer radiotherapy to a patient with widespread metastasis and a very limited life expectancy should be individualized (93).”
BackgroundSelf-citationResection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?
Gaujoux, S., Al‐Ahmadie, H. A., Allen, P. J., Gönen, M., Shia, J., D'Angelica, M. I., DeMatteo, R. P., Fong, Y., Blumgart, L. H., & Jarnagin, W. R. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2358-7 · Cited by 73 · cited 1×
“In a heterogeneous cohort of 28 patients with ACC and either synchronous or metachronous liver metastasis, surgical treatment of recurrence was an independent prognosticator of overall survival after adjusting for tumor laterality, hormone secretion, and the extent of initial hepatectomy (63).”
BackgroundBorderline Resectable Adrenal Cortical Carcinoma: A Potential Role for Preoperative Chemotherapy
Bednarski, B. K., Habra, M. A., Phan, A. T., Milton, D. R., Wood, C. G., Vauthey, N., Evans, D. B., Katz, M. H. G., Ng, C. S., Perrier, N. D., et al. (2014) · World Journal of Surgery · doi:10.1007/s00268-014-2484-4 · Cited by 73 · cited 1×
“In a retrospective study of 15 patients with BRACC treated with neoadjuvant chemotherapy and 38 patients with ACC treated with primary surgical resection, there was no statistically significant difference in median overall survival between the two groups, despite a more advanced disease in patients with BRACC; 5-year…”
MethodSelf-citationKerkhofs, T. M. A., Verhoeven, R. H. A., Bonjer, H. J., van Dijkum, E. J. M. N., Vriens, M. R., de Vries, J., van Eijck, C. H. J., Bonsing, B. A., van de Poll-Franse, L. V., Haak, H. R., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0142 · Cited by 71 · cited 1×
“The need for surgical and clinical expertise in management of ACC is supported by a recent study from the Netherlands, which showed significantly improved disease-free survival with the establishments of adrenal centers of excellence (18).”
BackgroundTiming of palliative care: When to call for a palliative care consult
Schlick, C. J. R., & Bentrem, D. J. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25499 · Cited by 71
Head, L., Kiseljak‐Vassiliades, K., Clark, T. J., Somerset, H., King, J., Raeburn, C. D., Albuja-Cruz, M. B., Weyant, M. J., Cleveland, J. C., Wierman, M. E., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00305 · Cited by 65 · cited 1×
“Early data suggests that combining other treatments such as mitotane may enhance the efficacy of immunotherapy (90).”
BackgroundSelf-citationAdjuvant Mitotane Therapy of Adrenal Cancer — Use and Controversy
Schteingart, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejme078087 · Cited by 62 · cited 1×
“Mitotane is an oral treatment that is available in 500-mg tablets (51).”
BackgroundLiver resection and ablation for metastatic adrenocortical carcinoma
Ripley, R. T., Kemp, C. D., Davis, J. L., Langan, R. C., Royal, R. E., Libutti, S. K., Steinberg, S. M., Wood, B. J., Kammula, U. S., Fojo, T., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1564-z · Cited by 62 · cited 2×
“Percutaneous radiofrequency ablation has been used successfully in patients with metastatic liver disease (70).”
BackgroundAdvanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Megerle, F., Kroiß, M., Hahner, S., & Faßnacht, M. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1946 · Cited by 59 · cited 1×
“The best imaging interval depends on a number of factors, including the dynamics of the disease, patient symptoms, toxicity and type of ongoing treatment, and the overall prognosis (72).”
BackgroundSirianni, R., Zolea, F., Chimento, A., Ruggiero, C., Cerquetti, L., Fallo, F., Pilon, C., Arnaldi, G., Carpinelli, G., Stigliano, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2374 · Cited by 58 · cited 1×
“In addition, one report suggested that ACC may express estrogen receptors, and as such, both physiologic and exogenous sources of estrogen may theoretically facilitate ACC growth (50).”
BackgroundWeissferdt, A., Phan, A. T., Suster, S. M., & Moran, C. A. (2013) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31828a96cf · Cited by 58 · cited 1×
“immunohistochemical stains that can help in the differential diagnosis and confirm adrenocortical tumor origin, such as inhibin-alpha, Melan-A, and calretinin (Table 4) (25,26).”
BackgroundImpact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients
Takeuchi, S., Balachandran, A., Habra, M. A., Phan, A. T., Bassett, R. L., Macapinlac, H. A., & Chuang, H. H. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2834-3 · Cited by 56 · cited 3×
“In a retrospective analysis of patients with ACC, 18FDG-PET changed the management plan in 9% of patients at restaging (8).”
BackgroundMethodInfluentialSelf-citationOperative intervention for recurrent adrenocortical cancer
Dy, B. M., Wise, K. B., Richards, M. L., Young, W. F., Grant, C. S., Bible, K. C., Rosedahl, J. K., Harmsen, W. S., Farley, D. R., & Thompson, G. B. (2013) · Surgery · doi:10.1016/j.surg.2013.06.033 · Cited by 53 · cited 1×
“Accordingly, resection of limited, potentially resectable hepatic or pulmonary metastases (60) needs to be discussed with this patient.”
BackgroundPhan, L. M., Fuentes‐Mattei, E., Wu, W., Velázquez-Torres, G., Sircar, K., Wood, C. G., Hai, T., Jiménez, C., Cote, G. J., Ozsari, L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3707 · Cited by 52 · cited 1×
“Targeting the cMET pathway appears to be promising, and there is an ongoing clinical trial to assess the safety and efficacy of cabozantinib in ACC (NCT03370718) (85).”
BackgroundSelf-citationNilubol, N., Patel, D., & Kebebew, E. (2015) · World Journal of Surgery · doi:10.1007/s00268-015-3283-2 · Cited by 50 · cited 1×
“While the benefit of regional prophylactic lymphadenectomy has not been extensively evaluated, several recent studies suggest a potential benefit of formal lymphadenectomy (21,22).”
BackgroundRenaudin, K., Smati, S., Wargny, M., Ghuzlan, A. A., Aubert, S., Leteurtre, E., Patey, M., Sibony, M., Stürm, N., Tissier, F., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0077-8 · Cited by 50
Greene, L. W., Geer, E. B., Page-Wilson, G., Findling, J. W., & Raff, H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00027 · Cited by 49 · cited 1×
“While an undetectable ACTH level would be expected in patients with autonomous glucocorticoid secretion, it is important to note that in most of the current clinically available assays, ACTH level might not be entirely suppressed even with overt ACTH-independent Cushing syndrome (14).”
BackgroundTherapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?
Baudin, É., Leboulleux, S., Ghuzlan, A. A., Chougnet, C., Young, J., Deandreis, D., Dumont, F., Dechamps, F., Caramella, C., Chanson, P., et al. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0094-2 · Cited by 47 · cited 1×
“Furthermore, very long survival has been reported in patients with oligometastatic disease with considerable intervals between recurrences (65).”
BackgroundAdrenocortical carcinoma and pregnancy: clinical and biological features and prognosis
Abiven-Lepage, G., Coste, J., Tissier, F., Groussin, L., Billaud, L., Dousset, B., Goffinet, F., Bertagna, X., Bertherat, J., & Raffin-Sanson, M.-L. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0412 · Cited by 46 · cited 1×
“As reported in a study of 12 women with ACC diagnosed during pregnancy or immediately postpartum, fetal outcomes were poor in more than half of cases, with premature birth, intrauterine growth retardation, and even intrauterine death (46).”
BackgroundImpact of Regional Lymph Node Dissection on Disease Specific Survival in Adrenal Cortical Carcinoma
Saade, N., Sadler, C., & Goldfarb, M. R. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1549877 · Cited by 45 · cited 1×
“While the benefit of regional prophylactic lymphadenectomy has not been extensively evaluated, several recent studies suggest a potential benefit of formal lymphadenectomy (21,22).”
BackgroundTessonnier, L., Ansquer, C., Bournaud, C., Sebag, F. A., Mirallié, É., Lifante, J. C., Palazzo, F. F., Morange, I., Drui, D., de la Foucardère, C., et al. (2012) · World Journal of Surgery · doi:10.1007/s00268-012-1802-y · Cited by 43 · cited 1×
“The most important ability of 18FDG-PET is to detect additional distant metastases, which may impact surgical decision making in this patient (58).”
BackgroundSurgical Management of Adrenocortical Carcinoma
Datta, J., & Roses, R. E. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.08.011 · Cited by 42
Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling
Bancos, I., & Arlt, W. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000333 · Cited by 42 · cited 2×
“In addition, urine steroid profiling has been emerging as a new tool of recurrence detection and is now available through Mayo Clinic Laboratories, but it has not yet been implemented in routine clinical practice (16,17,42,43).”
BackgroundMethodSelf-citationDelivanis, D. A., Erickson, D. Z., Atwell, T. D., Natt, N., Maraka, S., Schmit, G. D., Eiken, P. W., Nathan, M. A., Young, W. F., & Bancos, I. (2016) · Clinical Endocrinology · doi:10.1111/cen.13117 · Cited by 41
Self-citationSurgical treatment of adrenal carcinoma
Gaujoux, S., Weinandt, M., Bonnet, S., Reslinger, V., Bertherat, J. Y., & Dousset, B. E. (2017) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2017.06.010 · Cited by 40 · cited 1×
“The addition of 18FDG-PET to routine follow-up CT studies is suggested by some groups but not endorsed by the current guidelines (73).”
MethodSmith, C. B., Phillips, T., & Smith, T. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbk_175474 · Cited by 38
Yamazaki, Y., Nakamura, Y., Shibahara, Y., Konosu‐Fukaya, S., Sato, N., Kubota-Nakayama, F., Oki, Y., Baba, S., Midorikawa, S., Morimoto, R., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.10.017 · Cited by 37 · cited 1×
“It is important to gain experience with these automated systems, as they often provide different, in our experience, often higher values than traditional estimates (30,31).”
BackgroundA systematic review of palliative bone radiotherapy based on pain relief and retreatment rates
Pin, Y., Paix, A., Fèvre, C. L., Antoni, D., Blondet, C., & Noël, G. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.006 · Cited by 30 · cited 1×
“The available data demonstrates the effectiveness of palliative radiotherapy in the form of external beam radiation or stereotactic radiosurgery in symptom relief in up to 90% of patients with metastatic bone disease (96,97).”
BackgroundBerruti, A., Libé, R., Laganà, M., Ettaieb, H., Sukkari, M. A., Bertherat, J. Y., Feelders, R. A., Grisanti, S., Cartry, J., Mazziotti, G., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0026 · Cited by 28
Self-citationTripto-Shkolnik, L., Blumenfeld, Z., Bronshtein, M., Salmon, A., & Jaffe, A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2839 · Cited by 27
Oncocytic Lesions of the Neuroendocrine System
Canberk, Ş., LiVolsi, V. A., & Baloch, Z. W. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000011 · Cited by 26
Mills, J. K., Khalil, M., Pasieka, J. L., Kong, S., Xu, Y., & Harvey, A. M. (2019) · Surgery · doi:10.1016/j.surg.2019.05.049 · Cited by 26
Soga, H., Takenaka, A., Ooba, T., Nakano, Y., Miyake, H., Takeda, M., Tanaka, K., Hara, I., & Fujisawa, M. (2009) · Urologia Internationalis · doi:10.1159/000200804 · Cited by 25 · cited 1×
“Some data suggests better outcome for tumors less than 3 to 5 cm in size that are not near sensitive tissues or large blood vessels (69,71).”
MethodPregnancy in Women Previously Treated for an Adrenocortical Carcinoma
de Corbière, P., Ritzel, K., Cazabat, L., Ropers, J., Schott, M., Libé, R., Koschker, A., Leboulleux, S., Deutschbein, T., Cao, C. D., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2341 · Cited by 25 · cited 2×
“In contrast, in another study of 17 women with localized disease (majority with stage 1 or 2) treated with adrenalectomy (100%) and mitotane (71%), fetal outcomes were good, and overall survival was not affected by pregnancy when compared to matched controls (47).”
BackgroundResultAdrenal lesions in patients with extra-adrenal malignancy – benign or malignant?
Hammarstedt, L., Muth, A., Sigurjónsdóttir, H. Á., Almqvist, E. G., Wängberg, B., Hellström, M., & on behalf of The Adrenal Study Group of Western Sweden (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.608084 · Cited by 23
Ghorayeb, N. E., Rondeau, G., Latour, M., Cohade, C., Olney, H. J., Lacroix, A., Perrotte, P., Sabourin, A., Mazzuco, T. L., & Bourdeau, I. (2016) · Medicine · doi:10.1097/md.0000000000003180 · Cited by 23 · cited 1×
“Adjuvant mitotane therapy is generally continued for approximately a minimum of 2 years unless limited by intolerable adverse events and/or substantial recurrences in disease despite optimal mitotane dosing (54,55).”
BackgroundAdrenocortical Cancer Treatment
Long, S. E., & Miller, B. S. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.04.012 · Cited by 20 · cited 1×
“Different therapy algorithms have been suggested based on the site, size, and number of metastases (67).”
BackgroundHughes, M. S., Lo, W. M., Beresnev, T. H., Merino, M. J., Shutack, Y., Ripley, R. T., Hernandez, J. M., & Davis, J. L. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.06.012 · Cited by 17 · cited 1×
“It is unclear if this approach yielded any clinical benefit, as 2 patients died of disease within 2 years of follow-up, and the remaining 7 patients had evidence of disease recurrence (76).”
BackgroundPregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
Baszko-Błaszyk, D., Ochmańska, K., Waśko, R., & Sowiński, J. (2011) · PubMed · Cited by 15
Levine, A. C., Mitty, H. A., & Gabrilove, J. L. (1988) · The Journal of Urology · doi:10.1016/s0022-5347(17)41471-6 · Cited by 13
Self-citationGhander, C., Tissier, F., Tenenbaum, F., Silvera, S., Ragazzon, B., Bertherat, J. Y., BERTAGNA, X. Y., Dousset, B. E., Richard, B., Legmann, P., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3039 · Cited by 9 · cited 15×
“As the majority of ACCs express high levels of insulin-like growth factor 2, targeting insulin growth factor receptors has been attempted using a small-molecule kinase inhibitor (linsitinib) as part of the phase III GALACCTIC trial.”
BackgroundInfluentialRidho, F. E., Adam, F. M. S., & Adam, J. M. F. (2009) · PubMed · Cited by 9
Metastatic adrenal cortical carcinoma to T12 vertebrae
Lee, D. K., Yanamadala, V., Shankar, G. M., & Shin, J. H. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.11.009 · Cited by 7 · cited 1×
“as limb-saving procedures and vertebrectomy with spinal stabilization, provided the patient is suitable for surgery (98).”
BackgroundMiller, B. S. (2016) · Hormones and Cancer · doi:10.1007/s12672-015-0243-0 · Cited by 6
Prognosis of Patients with Metastatic Spinal Cord Compression from Adrenocortical Carcinoma.
Janssen, S., Bartscht, T., & Rades, D. (2016) · PubMed · Cited by 6
Cited by
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Libé, R., & Huillard, O. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100759 · Cited by 78
Hendricks, A., Müller, S., Faßnacht, M., Germer, C., Wiegering, V. A., Wiegering, A., & Reibetanz, J. (2022) · Cancers · doi:10.3390/cancers14020291 · Cited by 30
Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma
Kimpel, O., Schindler, P., Schmidt-Pennington, L., Altieri, B., Megerle, F., Haak, H. R., Pittaway, J. F. H., Dischinger, U., Quinkler, M. O., Mai, K., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02082-0 · Cited by 31
A review of mitotane in the management of adrenocortical cancer
Rivero, J. D., Else, T., Johnson, J. E. H., Kiseljak‐Vassiliades, K., Raj, N. P., Reidy‐Lagunes, D. L., Srinivas, S., Gilbert, J., Vaidya, A., Aboujaoude, E., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae084 · Cited by 30
Self-citation
Metadata
- Authors
- Kiseljak-Vassiliades, K., Bancos, I., Hamrahian, A., Habra, M. A., Vaidya, A., Levine, A. C., & Else, T.
- Affiliations
- Mayo Clinic (US)
- Johns Hopkins University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Michigan (US)
- Corresponding author
- Else, Tobias
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 26
- Issue
- 11
- Pages
- 1366-1383
- ISSN
- 1530-891X (ISSN-L)
- PMC
- PMC8058447
- OpenAlex
- W3107027801
- Cited by
- 66
- References
- 119
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 19 · 2023: 9 · 2022: 15 · 2021: 3
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 BX004665)
- National Cancer Institute (K08CA222620)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- adrenocortical carcinoma, adrenal tumors, adrenal imaging, mitotane, cytotoxic chemotherapy, radiofrequency ablation, multidisciplinary care, Li-Fraumeni syndrome, multiple endocrine neoplasia type 1
- MeSH terms
- Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Adult, Humans, Mitotane, Prospective Studies, United States, Adrenocortical Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.